Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Neuro-Oncology
•
Pediatric Hematology/Oncology
•
Neurology
•
Child Neurology
•
Neurogenetics
At what point should surgical intervention be considered for vestibular schwannomas or other tumors in pediatric NF2 patients?
Related Questions
How do you approach anti-seizure medication management when it was started by another team for a seizure-naive patient before/after craniotomy for a tumor?
Would you recommend anticoagulation in a pediatric patient with metastases in a dural venous sinus?
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
Would you recommend a specific workup or change in management for patients with severe, persistent deficits from methotrexate leukoencephalopathy?
What workup do you consider for a developmentally typical child with multiple large café au lait macules but no other signs of neurofibromatosis?
What are the best radiation therapy options for a young adult with 3 brain metastases from myeloid sarcoma that hasn’t responded well to intrathecal therapy?
Is there utility to ordering biochemical screening labs for global developmental delay?
Do you utilize tumor treating fields in patients with anaplastic pleomorphic xanthoastrocytoma (PXA) III?
What factors do you consider when determining eligibility for hematopoietic stem cell therapies for metachromatic leukodystrophy?
